191 related articles for article (PubMed ID: 8883145)
21. Human Ig production and isotype switching in severe combined immunodeficient-human mice.
Vandekerckhove BA; Jones D; Punnonen J; Schols D; Lin HC; Duncan B; Bacchetta R; de Vries JE; Roncarolo MG
J Immunol; 1993 Jul; 151(1):128-37. PubMed ID: 8326122
[TBL] [Abstract][Full Text] [Related]
22. Cloned human CD8+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism.
van Kuyk R; Torbett BE; Gulizia RJ; Leath S; Mosier DE; Koenig S
J Immunol; 1994 Nov; 153(10):4826-33. PubMed ID: 7963548
[TBL] [Abstract][Full Text] [Related]
23. HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model.
Taggart BR; Harrington P; Hollingshead M
Antiviral Res; 2004 Jul; 63(1):1-6. PubMed ID: 15196814
[TBL] [Abstract][Full Text] [Related]
24. Analysis of human blood cell development in the SCID-hu mouse, an in vivo replica of the human fetal hematopoietic system.
Péault B
C R Acad Sci III; 1993 Sep; 316(9):902-8. PubMed ID: 7521269
[TBL] [Abstract][Full Text] [Related]
25. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
26. Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice.
Garaci E; Aquaro S; Lapenta C; Amendola A; Spada M; Covaceuszach S; Perno CF; Belardelli F
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8927-32. PubMed ID: 12853577
[TBL] [Abstract][Full Text] [Related]
27. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.
Tanaka F; Abe M; Akiyoshi T; Nomura T; Sugimachi K; Kishimoto T; Suzuki T; Okada M
Cancer Res; 1997 Apr; 57(7):1335-43. PubMed ID: 9102222
[TBL] [Abstract][Full Text] [Related]
28. Identification of HIV-1 epitopes that induce the synthesis of a R5 HIV-1 suppression factor by human CD4+ T cells isolated from HIV-1 immunized hu-PBL SCID mice.
Yoshida A; Tanaka R; Kodama A; Yamamoto N; Ansari AA; Tanaka Y
Clin Dev Immunol; 2005 Dec; 12(4):235-42. PubMed ID: 16584108
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses.
Okuma K; Tanaka R; Ogura T; Ito M; Kumakura S; Yanaka M; Nishizawa M; Sugiura W; Yamamoto N; Tanaka Y
J Infect Dis; 2008 Jan; 197(1):134-41. PubMed ID: 18171296
[TBL] [Abstract][Full Text] [Related]
30. Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice.
Koup RA; Safrit JT; Weir R; Gauduin MC
Semin Immunol; 1996 Aug; 8(4):263-8. PubMed ID: 8883150
[TBL] [Abstract][Full Text] [Related]
31. Sulfatide administration leads to inhibition of HIV-1 replication and enhanced hematopoeisis.
Sundell IB; Halder R; Zhang M; Maricic I; Koka PS; Kumar V
J Stem Cells; 2010; 5(1):33-42. PubMed ID: 20861926
[TBL] [Abstract][Full Text] [Related]
32. Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections.
Kern ER; Rybak RJ; Hartline CB; Bidanset DJ
Antivir Chem Chemother; 2001; 12 Suppl 1():149-56. PubMed ID: 11594682
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice.
Nitsche A; Junghahn I; Thulke S; Aumann J; Radonić A; Fichtner I; Siegert W
Stem Cells; 2003; 21(2):236-44. PubMed ID: 12634420
[TBL] [Abstract][Full Text] [Related]
34. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
[TBL] [Abstract][Full Text] [Related]
35. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha.
Lapenta C; Santini SM; Logozzi M; Spada M; Andreotti M; Di Pucchio T; Parlato S; Belardelli F
J Exp Med; 2003 Jul; 198(2):361-7. PubMed ID: 12874266
[TBL] [Abstract][Full Text] [Related]
36. Deficient cytokine response of human allergen-specific T lymphocytes from humanized SCID mice and reconstitution by professional antigen-presenting cells.
Jarman ER; Perschke K; Montermann E; Herz U; Renz H; Knop J; Reske-Kunz AB
J Allergy Clin Immunol; 2000 May; 105(5):967-74. PubMed ID: 10808178
[TBL] [Abstract][Full Text] [Related]
37. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
Nakata H; Maeda K; Miyakawa T; Shibayama S; Matsuo M; Takaoka Y; Ito M; Koyanagi Y; Mitsuya H
J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
[TBL] [Abstract][Full Text] [Related]
38. SCID mouse models of human stem cell engraftment.
Greiner DL; Hesselton RA; Shultz LD
Stem Cells; 1998; 16(3):166-77. PubMed ID: 9617892
[TBL] [Abstract][Full Text] [Related]
39. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice.
Goldstein H; Pettoello-Mantovani M; Bera TK; Pastan IH; Berger EA
J Infect Dis; 2000 Mar; 181(3):921-6. PubMed ID: 10720513
[TBL] [Abstract][Full Text] [Related]
40. Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model.
Roth MD; Whittaker KM; Choi R; Tashkin DP; Baldwin GC
J Leukoc Biol; 2005 Dec; 78(6):1198-203. PubMed ID: 16204638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
